aurora 2 is related to lymph node metastasis in colon and gastric carcinoma

aurora 2与结肠癌和胃癌淋巴结转移相关

• 批准号: 12671232
• 负责人: SADANAGA Noriaki
• 金额: $ 2.18万
• 依托单位: KYUSHU UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12671232/
• 关键词: cell cycle regulator; aurora 2; colon cancer; gastric cancer; lymph node metastasis; aurora2; 消化器癌; 癌の悪性度

Backgrounds: Aurora2 is a family of human serine/threonine kinases characterized as cell cycle regulators. In this study, we evaluated the expression of aurora 2 mRNA in gastro-intestinal carcinoma and the correlation between overexpression and clinico-pathological factors. Material and methods: We studied the 201 Japanese patients with carcinoma of gastrointestinal tract, including 53 esophageal cancer, 72 gastric cancer and 76 colorectal cancer. The expression of aurora 2 was investigated by RT-PCR. Results: Aurora 2 mRNA was expressed in 27 of 53 (51%) esophageal cancer, 38 of 72 (53%) gastric cancer and 36 of 76 (46%) colorectal cancer. The relations between the aurora2 expression and the clinicopathological factors was examined. In gastric carcinoma, lymph node metastasis was shown in 27 of 38 (71%) cases with aurora2 expression positive group, more frequent than those with negative expression (p<0.01). In colon carcinoma, lymph node metastasis was present in 23 of 36 (64%) cases with expression positive group and in 7 of 40 (18%) without, a statistically significant difference (p<0.01). There was lymphatic vessel invasion in 25 of 36 (69%) in the aurora2 expression positive group but in only 12 of 40 (30%) in the negative group (p<0.01). There was a significant differences between the two groups in Dukes classification (p<0.01). The overall 5-year survival rate for patients with aurora2 overexpression was lower than for patients without expression in colorectal cancer (92% vs. 64%, p<0.05). Conclusions: These results suggested that aurora2 expression was associated with tumor progression and patients survival and may be a new prognostic indicator for patients with colon carcinoma.

背景：Aurora2是一个人类丝氨酸/苏氨酸激酶家族，其特征是细胞周期调节因子。在本研究中，我们评估了极光2 mRNA在胃肠道肿瘤中的表达及其与临床病理因素的相关性。材料与方法：对201例日本胃肠道癌患者进行研究，其中食管癌53例，胃癌72例，结直肠癌76例。采用RT-PCR技术检测极光2的表达情况。结果：53例食管癌中27例（51%）、72例胃癌中38例（53%）、76例结直肠癌中36例（46%）表达了Aurora 2 mRNA。探讨aurora2表达与临床病理因素的关系。38例胃癌中，aurora2阳性表达组有27例（71%）出现淋巴结转移，高于阴性表达组（p<0.01）。在结肠癌中，表达阳性组36例中有23例（64%）出现淋巴结转移，未表达阳性组40例中有7例（18%）出现淋巴结转移，差异有统计学意义（p<0.01）。aurora2阳性表达组36例中有25例（69%）出现淋巴管侵犯，阴性表达组40例中仅有12例（30%）出现淋巴管侵犯（p<0.01）。两组间Dukes分型差异有统计学意义（p<0.01）。在结直肠癌中，aurora2过表达患者的总体5年生存率低于无表达患者（92% vs. 64%, p<0.05）。结论：这些结果提示，aurora2表达与肿瘤进展和患者生存相关，可能是结肠癌患者预后的新指标。

项目成果

Mori M.et al.: "Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma"Cancer Res. 61. 7379-7382 (2001)

Mori M.等人：“Msh2 蛋白表达的缺失与结直肠癌中 FHIT 位点和 Fhit 蛋白表达的改变有关”Cancer Res。

Tahara K. et al.: "MAGE-specific cytotoxic T lymphocytes require non-specific CD54 adherence receptors on carcinoma cells."Int J Oncol. 17. 805-810 (2000)

Tahara K. 等人：“MAGE 特异性细胞毒性 T 淋巴细胞需要癌细胞上的非特异性 CD54 粘附受体。”Int J Oncol。

Mori M et al.: "Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus"Cancer Res.. 60・5. 1177-1182 (2000)

Mori M等：“食管癌和癌前病变中Fhit的表达改变”Cancer Res. 1177-1182 (2000)。

Kataoka A. et al.: "RT-PCR detection of breast cancer cells in sentinellymph nodes."Int J Oncol. 16. 1147-1152 (2000)

Kataoka A. 等人：“RT-PCR 检测前哨淋巴结中的乳腺癌细胞。”Int J Oncol。

Matsuyama A et al: "Hepatoma-derived growth factor is associated witn reduced sensitivity to irradiation in esophageal cancer"Cancer Res. 61. 5714-5717 (2001)

Matsuyama A 等人：“肝癌衍生生长因子与食道癌对辐射的敏感性降低有关”Cancer Res。